Effect and Mechanism of Modified Erchentang on Immune Function, CCL18, CC16, IL-8 and sICAM-1 in Patients at Acute Exacerbation Stage of COPD

Si-qing CHEN,Wen-ying XIE,Li-zhi SHANG,Hong-li XUE,Zhi-yong LIU,Hong-yan DU,Xian-min ZHAO,Xiao-hui LIU,Chun-yang SUN,Shu JI,Chang-qing LU,Miao ZHANG,Juan-juan LIANG,Yi WANG
DOI: https://doi.org/10.13422/j.cnki.syfjx.2017100171
2017-01-01
Abstract:Objective:To observe the effect and mechanism of modified Erchentang on immune function,chemoattractant cytokine 18 (CCL18),interleukin-8 (IL-8),clara cell protein (CC16) and soluble intercellular adhesion molecular-1 (sICAM-1) in patients at acute exacerbation stage of COPD (AECOPD).Method:Totally 120 cases of elder AECOPD patients were randomly divided into modified Erchentang group and placebo-controlled group,with 60 cases in each group.In addition to western drugs,modified Erchentang was also used in modified Erchentang group,and placebo was also used in control group for 14 days.Their pulmonary function was detected,and euzyme-linked immunosorbent assay was used to determine the levels of CCL18,CC16,IL-8 and sICAM-1 in patients' plasma and exhaled breath condensate of all groups before and after treatment.Result:Compared with control group,treatment group showed increases in total effective rate (P < 0.05),and FEV1 and FEV1% (P < 0.01),but decreases in total inflammatory cell counts,neutrophil counts,monocytes and lymphocytes (P < 0.05).Compared with before treatment,the group showed no significant difference in IgG,IgA,IgM,increases in CD3+,CD4+,CD4+/CD8 +and decreases in CD8+,CCL18,CC16,IL-8,sICAM-1,CCL18 and CC16 in EBC (P < 0.05).Conclusion:Modified Erchentang has an anti-inflammatory effect on AECOPD by reducing level of inflammation medium CCL18,CC16,IL-8 and sICAM-1,preventing inflammation progress and adjusting the immune function.
What problem does this paper attempt to address?